DocWire News Editors

DocwireNews

In a controlled clinical trial, researchers found that the expression of PD1 and various microparticles were associated with proliferation and resistance to standard treatment in multiple myeloma (MM). Their findings were published in Scientific Reports. According to lead study author, Asmaa M. Zahran, the study&rsquo;s examination of PD1 and different microparticles &ldquo;suggested that they played a crucial role in myeloma progression.&rdquo;&nbsp;Thirty patients with newly diagnosed MM, along with 19 healthy participants of comparable age and sex, were enrolled in the study. All participants&rsquo; blood was collected for flow cytometric detection of CD4+, CD8+, CD4+PD1+, and CD8+PD1+T cells, total microparticles, CD138+ microparticles, and platelet microparticles.MM patients had significantly higher levels of total microparticles and CD138+ microparticles compared to the control group, while platelet microparticles exhibited no significant difference between the two groups. Patients with MM exhibited significantly higher percentages of CD8+, PD1CD8+, and PD1CD4+T cells compared to controls, while the control group had a significantly higher percentage of CD4+T cells than MM patients.Patients who did not achieve complete response had significantly higher percentages of platelet microparticles, CD138+ microparticles, PD1+CD8+, PD1+CD4+, and CD8+T cells (cutoff values = 61, 10.6, 13.5, 11.3, and 20.1, respectively; p = 0.002, 0.003, 0.017, 0.001 and 0.008 respectively).The study&rsquo;s authors ultimately surmised that expression of various microparticles and PD1 could be associated with proliferative potential and resistance to bortezomib-based treatments in patients with MM, and that they appear to play a role in disease progression as well.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Association of Microparticles and PD1 With Prognosis in Patients With Multiple Myeloma

Oncology

In a controlled clinical trial, researchers found that the expression of PD1 and various microparticles were associated with proliferation and resistance to standard treatment ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe